media – Page 4 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Johnson&Johnson’s first PFA product receives FDA approval for market launch

Recently, Johnson&Johnson announced that it has received approval from the US Food and Drug Administration (FDA) for its Varipulse pulsed field ablation system, which can be used to treat drug-resistant paroxysmal atrial fibrillation. After obtaining approval, Johnson&Johnson became the third company in the United States to have PFA technology for treating AFib, joining the ranks of Medtronic and Boston Scientific, and the PFA market’s top three competition officially opened. With the support of an ace, Johnson&Johnson has strong competitive strength It is understood that the Varipulse pulsed field ablation system consists of a Varipulse ablation catheter and a TRUPULSE generator. Among them, the VARIPULSE ablation catheter was developed based on Johnson&Johnson’s previous mapping catheter LASSO catheter, which is a continuation of LASSO catheter technology and further demonstrates Johnson&Johnson’s deep technical reserves in the catheter field. The Varipulse ablation catheter has 10 electrodes on the annular tip, and the size of ...
- Source: drugdu
- 51
- November 14, 2024
270 million! Chinese medicine giant acquires 100% equity of innovative pharmaceutical company

Chinese medicine companies are beginning to acquire innovative pharmaceutical companies. 01 270 million yuan Kangyuan Pharmaceutical acquires 100% equity of Zhongxin Pharmaceutical On November 7th, Kangyuan Pharmaceutical released an announcement on the acquisition of 100% equity of Jiangsu Zhongxin Pharmaceutical Co., Ltd. and related party transactions. It plans to acquire 100% equity of Zhongxin Pharmaceutical with its own funds of 270 million yuan. After the completion of this transaction, Zhongxin Pharmaceutical will become a wholly-owned subsidiary of Kangyuan Pharmaceutical.In this transaction, Kangyuan Pharmaceutical’s controlling shareholder Kangyuan Group holds 70% equity of Zhongxin Pharmaceutical, corresponding to a transfer price of 189 million yuan. Kangyuan Pharmaceutical will make the first payment of 60%, or 113.4 million yuan, to Kangyuan Group, and the remaining 40%, or 75.6 million yuan, will be paid in installments after the corresponding pipeline drugs of Zhongxin Pharmaceutical obtain marketing authorization. Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) holds ...
- Source: drugdu
- 44
- November 14, 2024
Wang Lei is discussing with lawyer

The first step in stock trading is to open a stock account On November 12th local time, Pascal Soriot, the global CEO of AstraZeneca, publicly responded for the first time to the detention of Wang Lei, the company’s China regional president. Suboko said, “Wang Lei is discussing with his lawyer, and the company does not have any new information about the case Suboko made the above response after the release of AstraZeneca’s third quarter financial report. He also said, “We attach great importance to the issues in the Chinese market and are taking measures to further strengthen compliance However, he denied that AstraZeneca headquarters lacked supervision over compliance. He said that the company has over 16000 employees in China, unfortunately some people may be tempted to maximize sales. He also stated that AstraZeneca has strengthened its compliance team of over 200 people in China and introduced resident compliance officers to ...
- Source: drugdu
- 48
- November 14, 2024
Two innovative medical devices were approved for marketing

Recently, the National Medical Products Administration announced the approval of two innovative product registration applications: “Brain Surgery Planning Software” by Beijing Huake Precision Medical Technology Co., Ltd. (hereinafter referred to as Huake Precision) and “Implantable Deep Brain Neurostimulation Extension Lead” by Boston Scientific Neuromodulation Company (hereinafter referred to as Boston Scientific). Huake Precision focuses on the research and development, production and technical services of intelligent and innovative medical devices. It is a leading company in China’s innovative neurosurgery medical devices, providing comprehensive technology and product solutions for the treatment of brain diseases. It is reported that Huake Precision currently has five major product lines including the SR series of neurosurgery robots, the Q300 series of micro neurosurgery robots, the NS series of neurosurgery navigation, the Huake Hengsheng intracranial electrode series, and the LS series of magnetic resonance guided laser ablation treatment systems. It has built a full-chain technology system including ...
- Source: drugdu
- 44
- November 14, 2024
Medicare Fund Prepayment System Introduced, Benefiting Pharmaceutical Sector; Pharmaceutical Stocks Surge

Recently, the National Healthcare Security Administration (NHSA) and the Ministry of Finance released a notice titled “Notice on Effectively Implementing Medicare Fund Prepayment Work” (hereinafter referred to as “the Notice”). This initiative supports certain regions in further improving the management methods for prepayment funds, aiming to alleviate the financial burden of medical expenses for designated medical institutions. It incentivizes these institutions to provide better healthcare services to insured individuals. The announcement led to a significant surge in pharmaceutical stocks yesterday. By the close of trading, companies such as Changyao Holdings, Weikang Pharmaceutical, Guangzheng Ophthalmology, and Wanbangde had hit their daily limit, while Lukang Pharmaceutical and Purui Ophthalmology also saw substantial gains. It’s noteworthy that the stocks that surged included a variety of sectors, spanning specialized hospitals and pharmaceutical companies. The CSI Medical Index rose by 1.2%, the CSI 300 Medical and Health Index increased by 0.97%, and the CSI Innovative ...
- Source: drugdu
- 33
- November 14, 2024
Innovative Drug Leader Breaks $1 Billion in Quarterly Revenue for the First Time

Last night, BeiGene Ltd, a leader in innovative pharmaceuticals, released its third-quarter report for 2024. The company achieved operating revenue of 7.139 billion yuan (approximately $1.03 billion), marking a year-on-year increase of 26.9%. However, the net profit attributable to the parent company reported a loss of 809 million yuan, a decline of 160.4% compared to the same period last year. This marks the first time the company’s quarterly revenue has exceeded $1 billion. BeiGene attributed the increase in third-quarter revenue primarily to higher product sales compared to the same period last year. The decrease in net profit, on the other hand, was mainly due to a non-cash gain recognized from a settlement with Bristol-Myers Squibb (BMS) in the previous year. It is worth noting that in the financial data for the first three quarters, the company has faced pressure in cash flow management, recording a net cash flow from operating ...
- Source: drugdu
- 33
- November 14, 2024
AstraZeneca’s Global CEO Responds for the First Time to the Detention of Chinese Executive

On November 12, local time, Pascal Soriot, the Global CEO of AstraZeneca, publicly responded for the first time to the detention of the company’s China President, Wang Lei. Soriot stated, “Wang Lei is discussing the matter with his lawyer, and the company does not have any new information regarding the case.” Soriot made these comments following the release of AstraZeneca’s third-quarter financial report. He emphasized, “We take issues related to the Chinese market very seriously and are taking measures to enhance compliance.” However, he denied that AstraZeneca’s headquarters lacked oversight on compliance matters. He noted that the company has over 16,000 employees in China and lamented that some individuals may succumb to “temptation” to maximize sales. Moreover, he mentioned that AstraZeneca has strengthened its compliance team in China, which consists of over 200 members, and has introduced resident compliance officers who use artificial intelligence to review expense reports from sales ...
- Source: drugdu
- 37
- November 14, 2024
Pharma Asia

Organiser：ECG Limited, Pakistan Time：December 2 – 4, 2025 Address：University Rd, Gulshan-e-Iqbal, Karachi, Pakistan Exhibition hall：Karachi Expo Center Product range: Medical Products Zone: Medical diagnostic equipment and supplies, electronic medical devices and instruments, emergency rescue equipment, medical reagents and equipment, etc. Hospital Supplies Zone: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical instruments, medical clothing and bedding, emergency equipment, maternal and child care equipment, disinfection equipment, etc. Laboratory Equipment Zone: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, laboratory renovation and retrofitting technologies, consumables, and related software, etc. Pharmaceuticals Zone: Various new and special drugs, Chinese patent medicines, western medicines, traditional Chinese medicine health products, nutritious foods, etc.; Traditional medicines: Chinese herbal medicines, herbal remedies, etc. Pharmaceutical Equipment Zone: Pharmaceutical production equipment and technology, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, cleaning, and disinfection systems. About Pharma ...
- Source: drugdu
- 46
- November 14, 2024
Seizing the “Golden Race” of Synthetic Biology

On November 8th, Hangzhou, Zhejiang Province held a conference on the high-quality development of the synthetic biology industry and released the “Three Year Action Plan for the High Quality Development of the Synthetic Biology Industry in Hangzhou (2024-2026)” (hereinafter referred to as the “Three Year Action Plan”). According to the “Three Year Action Plan”, Hangzhou aims to implement five major actions, including breakthroughs in core technology, upgrading of platform capabilities, cultivation of enterprise tiers, strengthening of industrial clusters, and optimization of industrial ecology. The goal is to achieve a total output value of 40 billion yuan in the city’s synthetic biomanufacturing industry by 2026. According to incomplete statistics, Hangzhou currently has more than 260 synthetic biology related enterprises, with a production value of over 25 billion yuan by 2023. Shen Kaibo, Deputy Secretary General of Hangzhou Municipal Government, stated that with the release of the “Three Year Action Plan”, Hangzhou ...
- Source: drugdu
- 51
- November 13, 2024
Four innovative pharmaceutical companies have completed a new round of financing! 3 from China

According to the Instant Drug Database, last week (November 4th to November 10th), at least four emerging companies dedicated to innovative drug research and development worldwide announced the completion of a new round of financing, including three Chinese companies. These emerging companies that have gained favor in the capital market are developing drug types such as gene therapy drugs, iPSC cell therapy drugs, peptide vaccines, and antibody conjugated drugs (ADCs) with dual payloads. Kanglin Biotechnology Financing round: Series A Financing amount: 150 million yuan On November 8th, Kanglin Biotechnology (Hangzhou) Co., Ltd. (referred to as “Kanglin Biotechnology”) announced the completion of a 150 million yuan Series A financing, jointly invested by Zhejiang Province’s “4+1” Biomedical and High end Device Industry Fund and old shareholder Zhejiang Miyin Investment Management Co., Ltd. Kanglin Biology was founded in 2015, focusing on the R&D and commercialization of innovative drugs for gene therapy, targeting diseases ...
- Source: drugdu
- 51
- November 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.